NEWAMSTERDAM PHARMA CO NV (NAMS) Stock Earnings & Estimates
USA - NASDAQ:NAMS - NL00150012L7 - Common Stock
37.97 USD
-2.48 (-6.13%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 97.5M | 13.254M -86.41% | 32.622M 146.13% | 30.38M -6.87% | 30.887M 1.67% | 140.1M 353.59% | 312.38M 122.97% | 579.46M 85.50% | 958.68M 65.44% | 1.321B 37.79% | 1.573B 19.08% | |||
| EBITDA YoY % growth | -126.7K | -1.352M -967.32% | -3.867M -185.96% | -218.688M -5,555.24% | -192.78M 11.85% | -226.496M -17.49% | -153.087M 32.41% | -18.435M 87.96% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -127.7K | -1.366M -969.93% | -3.939M -188.30% | -192.371M -4,783.75% | -190.345M 1.05% | -220.095M -15.63% | -250.181M -13.67% | -239.554M 4.25% | -102.995M 57.01% | 124.57M 220.95% | 463.14M 271.79% | 770.9M 66.45% | 927.68M 20.34% | |
| Operating Margin | N/A | N/A | -4.04% | -1,451.42% | -583.49% | -724.47% | -809.99% | -170.99% | -32.97% | 21.50% | 48.31% | 58.36% | 58.98% | |
| EPS YoY % growth | N/A | N/A | N/A | -2.21 -1,306.89% | -2.12 -16.91% | -1.42 44.95% | -1.93 -36.14% | -1.80 6.73% | -0.86 52.26% | 0.78 190.14% | 2.76 255.43% | 4.02 45.87% | 5.18 28.76% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.43 -138.85% | -0.45 51.19% | -0.48 -42.41% | -0.50 -232.23% | -0.49 -13.69% | -0.51 -12.58% | -0.49 -1.11% | -0.57 -14.62% | -0.52 -6.43% | -0.47 8.18% |
| Revenue Q2Q % growth | 3.125M -89.27% | 5.415M -57.60% | -100.00% | -100.00% | -100.00% | 297.84K -94.50% | 734.4K | 1.112M | 7.477M | 13.474M 4,423.91% |
| EBITDA Q2Q % growth | -64.213M | -66.7M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -55.605M -5.91% | -57.824M -6.50% | -68.005M -17.04% | -69.823M -7.04% | -64.297M -15.63% | -68.299M -18.12% | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.15 63.41% | -0.50 | 0.35 | 70.09% |
| Q1 2025 Q2Q % growth | -0.34 67.92% | -0.50 | 0.16 | 31.66% |
| Q4 2024 Q2Q % growth | -0.93 -60.07% | -0.50 | -0.43 | -87.61% |
| Q3 2024 Q2Q % growth | -0.18 67.54% | -0.51 | 0.33 | 64.67% |
| Q2 2024 Q2Q % growth | -0.41 11.09% | -0.59 | 0.18 | 30.32% |
| Q1 2024 Q2Q % growth | -1.06 -163.31% | -0.54 | -0.52 | -97.14% |
| Q4 2023 Q2Q % growth | -0.58 -26.72% | -0.61 | 0.03 | 4.67% |
| Q3 2023 Q2Q % growth | -0.55 4.59% | -0.50 | -0.06 | -11.52% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 19.145M 740.06% | 1.63M | 17.515M | 1,074.54% |
| Q1 2025 Q2Q % growth | 2.978M 112.56% | 1.607M | 1.371M | 85.31% |
| Q4 2024 Q2Q % growth | 12.772M 1,521.66% | 1.791M | 10.981M | 613.12% |
| Q3 2024 Q2Q % growth | 29.111M 877.73% | 1.91M | 27.201M | 1,424.14% |
| Q2 2024 Q2Q % growth | 2.279M -76.17% | 1.406M | 873K | 62.09% |
| Q1 2024 Q2Q % growth | 1.401M -45.10% | 1.778M | -377K | -21.20% |
| Q4 2023 Q2Q % growth | 787.59K -99.19% | 1.998M | -1.21M | -60.58% |
| Q3 2023 Q2Q % growth | 2.977M | 2.291M | 686.42K | 29.96% |
| Q2 2023 Q2Q % growth | 9.562M | 2.794M | 6.768M | 242.23% |
| Q4 2022 Q2Q % growth | 97.5M | 3.561M | 93.939M | 2,637.99% |
| Q3 2022 Q2Q % growth | 1.687M | -1.687M | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | -16.39% |
| Revenue | 0% | 0% | 0% | 86.41% |